Document:

Exhibit 10.1

                            EMPLOYMENT AGREEMENT

                  EMPLOYMENT AGREEMENT (this "Agreement"),  made effective as of
January 1, 2000, by and between Remington  Products Company,  L.L.C., a Delaware
limited  liability  (the  "Company"),  and Neil P.  DeFeo,  an  individual  (the
"Executive").

                              W I T N E S S E T H:
                              --------------------

                  WHEREAS,  the Company desires to retain  Executive to serve it
in the capacity of President and Chief Executive Officer and to perform services
on its behalf in said position;

                  NOW,  THEREFORE,  in consideration of the foregoing and of the
mutual promises and covenants herein  contained,  the receipt and sufficiency of
which are hereby acknowledged, the parties hereto agree as follows:

                  1.       EMPLOYMENT

                  The Company agrees to employ Executive and Executive agrees to
serve the Company on the terms and conditions set forth herein.

                  2.       TERM

                  This Agreement shall be for an initial period of two (2) years
(the "Initial Term"); provided that the term of this Agreement shall be extended
for two years  unless six months  prior to the  second  anniversary  of the date
hereof,  the Company  notifies  the  Executive,  or three  months  prior to such
anniversary,  the Executive  notifies the Company,  that the  Agreement  will be
terminated at the end of the Initial Term.  Successive two-year extensions occur
thereafter  in the same  manner  unless  notice of  termination  is given by the
Company at least six months or by the Executive at least three months,  prior to
the end of the then  effective  Term.  As used herein,  "Term" means the Initial
Term and any extensions thereof as provided for in this Section 2.

                  3.       POSITION AND DUTIES

                  (a)  Executive  shall  serve as Chief  Executive  Officer  and
President  of the  Company  and shall  perform  such  duties and  exercise  such
supervision  and powers  over and with  regard to the  business  of the  Company
customarily  associated  with  the  position  of  Chief  Executive  Officer  and
President,  as well as such duties and services  prescribed herein and as may be
reasonably  prescribed  from  time to time by the  Management  Committee  of the
Company (the  "Board").  Executive  shall perform such duties to the best of his
ability and in a diligent  and proper  manner.  Executive  shall be appointed to
serve as a member  of the  Board  during  the  term of his  employment  with the
Company.

                  (b) Except during vacations and periods of illness,  Executive
shall,  during  the term of this  Agreement,  devote all his  business  time (as
opposed to personal  time) and attention to the  performance of services for the
Company.  The Executive shall  cooperate  reasonably in any sale of the Company,
IPO or similar transaction. The Executive shall have the right to serve on other
boards of directors and engage in civic and  charitable  activities,  subject to
the consent of the Company, which consent shall not be unreasonably withheld.

                     4.       COMPENSATION AND RELATED MATTERS

                  (a)  Salary.  During  the  period  of  Executive's  employment
hereunder,  the  Company  shall pay to  Executive a salary at a rate of not less
than $600,000 per annum payable in accordance  with normal payroll  practices of
the Company but not less frequently than monthly.  The Executive's  salary shall
be  reviewed  annually  and may be  increased  based on such  review  and, if so
increased,  shall not thereafter be decreased during the Term of this Agreement,
except  that it may be  decreased  in  connection  with a general  reduction  of
salaries of executives,  but in no event to less than $600,000.  As used herein,
"Base  Salary"  means  Executive's  initial  salary  hereunder  as the  same  is
increased.  The salary  payments  hereunder shall not in any way limit or reduce
any  other  obligation  of the  Company  hereunder,  and no other  compensation,
benefit or payment  hereunder shall in any way limit or reduce the obligation of
the Company to pay Executive's Base Salary hereunder.

                  (b) Welfare and Retirement  Benefits.  From and after the date
of this  Agreement,  Executive  shall be entitled to  participate  in all of the
Company's employee pension plans,  welfare benefit plans,  tax-deferred  savings
plans, or other welfare or retirement  benefits or  arrangements  (including any
insurance  or trust  arrangements  maintained  generally  for the benefit of the
Company's  directors and  officers)  and in which the executive  officers of the
Company are  entitled  generally  to  participate  (collectively,  the  "Company
Benefit  Plans") on the same basis as other  executive  employees.  The  Company
shall provide the Executive  with term life  insurance in the amount of at least
two times base  salary  (insurance  provided  pursuant to the  existing  Company
Benefit Plan shall count  towards the foregoing  amount).  The Company shall use
its best  efforts  to enable  the  Executive  to  purchase  up to an  additional
$500,000 in term life insurance at the Executive's expense.

                  (c)  Bonus/Incentive  Compensation.  (i) The  Board  shall (A)
establish   performance  targets  based  on  profits  of  the  Company  and  its
consolidated  subsidiaries and other reasonable  financial criteria at or around
the  commencement  of each fiscal year and (B)  establish a target for aggregate
bonuses for the  Company's  executives  for each fiscal year (the "Bonus  Pool")
which  may  increase  or  decrease  depending  upon  the  extent  to  which  the
performance criteria for such fiscal year are achieved.  Executive's  percentage
of the Bonus Pool will be set so that Executive will receive a bonus of not less
than 85% of Base  Salary  in the event  that the  Company  achieves  100% of the
criteria  established  for such year (the  "Target  Bonus").  The  amount of the
Target Bonus will be adjusted,  in  accordance to the terms of the bonus program
adopted by the Company,  (including any special accelerated bonus program) based
on Company Performance above or below the targeted performance level.

     (ii) In addition to any bonus  payable  under  clause (i) above,  Executive
will be entitled to receive an additional  $250,000 as a bonus in the event that
the EBITDA (as  defined  under the bonus plan for the  Company)  of the  Company
exceeds  $43,000,000  for the fiscal year 2000,  taking into account any bonuses
paid under the  Company  bonus plan for such fiscal  year  (including  the bonus
payable  under this clause  (ii)).  Such bonus shall be payable when the bonuses
are  payable  under  Clause  (i) in respect of such  fiscal  year.  The Board of
Directors  shall consider  similar bonuses (at new targets) for each fiscal year
under appropriate circumstances.

                  (d)  Vacations.  Executive  shall be entitled to the number of
paid  vacation days in each  calendar  year  determined  in accordance  with the
Company's vacation policies but in no event less than four weeks.

                  (e)  Expenses.  During  the  term  of  Executive's  employment
hereunder,  Executive shall be entitled to receive prompt reimbursement from the
Company of all  reasonable  business-related  expenses  incurred by Executive in
performing  services  hereunder,  including  all  expenses  of travel and living
expenses  while  away from home on  business  or at the  request  of, and in the
service of, the Company;  provided that such expenses are incurred and accounted
for in accordance  with the policies and  procedures  established by the Company
from time to time.

                  (f)      Certain Benefits

                           (1) Facilities and Services The Company shall furnish
                           Executive with office space,  secretarial  assistance
                           and such other  facilities  and  services as shall be
                           suitable to Executive's position and adequate for the
                           performance  of his  duties  set  forth in  Section 3
                           hereof.

                           (2) Company  Car.  The  Company  shall lease a car of
                           Executive's choice to be used by Executive during the
                           term of this Agreement,  provided that lease payments
                           shall not exceed one  thousand  dollars  ($1,000) per
                           month.

                           (3) Country Club Dues.  The Company  shall  reimburse
                           Executive  for (i)  annual  dues and (ii)  reasonable
                           annual  expenses of  membership  in a country club of
                           his choice incurred during the term of this Agreement
                           in connection  with the  performance  of  Executive's
                           services under this Agreement.

                           (4) Financial Planning. The Company shall pay up to
                           $10,000 in each year of the term of this Agreement
                           for financial planning services for Executive.

                  5.       TERMINATION

                  Executive's  employment  hereunder may be terminated under the
following circumstances:

                  (a)      Death.  Executive's employment hereunder shall
                           terminate upon his death.

                  (b) Disability. If Executive is unable to timely and regularly
perform  his duties  hereunder  due to  physical  or mental  illness,  injury or
incapacity,  as determined by the Board in good faith, based on medical evidence
acceptable to it (a "Disability") and such Disability  continues for a period of
six consecutive months,  then,  notwithstanding the provisions of Section 2, the
Company may terminate  Executive's  employment  hereunder.  A return to work for
less than thirty  consecutive  days during any period of Disability shall not be
deemed to interrupt the running of (and shall be included in) the aforementioned
six-month period.

                  (c) Cause.  The Company may terminate  Executive's  employment
hereunder at any time for Cause.  For purposes of this Agreement,  "Cause" shall
mean a  termination  of  employment  of the  Executive  by  the  Company  or any
subsidiary thereof due to (i) the commission by the Executive of an act of fraud
or  embezzlement  (including  the  unauthorized  disclosure of  confidential  or
proprietary information of the Employer or any of its subsidiaries which results
in material financial loss to the Company or any of its subsidiaries),  (ii) the
commission by Executive of a felony (A) materially  involving the Company or (B)
materially  affecting the Executive's  ability for a sustained period to perform
services in the manner required  hereunder,  (iii) the willful misconduct of the
Executive  as an  employee of the  Company or any of its  subsidiaries  which is
reasonably  likely to result in material injury or financial loss to the Company
or any of its  subsidiaries  or, (iv) the willful  failure of the  Executive  to
render services to the Company or any of its subsidiaries in accordance with the
Executive's  employment  which  failure  amounts  to a  material  neglect of the
Executive's  duties to the Company or any of its subsidiaries,  or (v) a willful
material  breach of the  covenants in Section 3(a) (but only in the  penultimate
sentence thereof), Section 3(b) and Sections 10 or 11 hereof by Executive, which
breach is not cured within thirty (30) days after written  notice of such breach
is delivered to Executive. Executive shall not be deemed to have been terminated
for Cause unless the Company  shall have given or  delivered  to  Executive  (1)
reasonable   notice   setting  forth,   in  reasonable   detail  the  facts  and
circumstances,  if any, claimed to provide a basis for termination for Cause and
(2) a reasonable  opportunity  for Executive,  together with his counsel,  to be
heard before the Board.

                  For  purposes  of  determining  whether  Executive  was  given
"reasonable notice" and "reasonable  opportunity to be heard" in connection with
any  determination  by the Board as to whether  Cause  exists,  10 business days
notice of the Board meeting shall be deemed to  constitute  "reasonable  notice"
(without  prejudice to the determination of whether some other period would also
constitute  "reasonable  notice")  and the  opportunity  for  Executive  and his
counsel to present  arguments to the Board at such  meeting as to why  Executive
believes that no Cause exists shall  constitute  "reasonable  opportunity  to be
heard" (without  prejudice to the  determination  of whether some other forum or
method would also constitute a "reasonable opportunity to be heard").

                  (d)  Termination  by Executive for Good Reason.  Executive may
voluntarily  terminate his employment hereunder at any time for Good Reason. For
purposes of this  Agreement,  "Good Reason" shall mean (i) a material  breach of
this  Agreement by the Company  which has not been cured within thirty (30) days
after the  Board's  receipt of written  notice of such  non-compliance  from the
Executive;  (ii) the assignment to Executive by the Company of duties materially
and adversely inconsistent with Executive's position, duties or responsibilities
as in  effect  immediately  after  the  date  of  execution  of  this  Agreement
including,  but not limited to, any material reduction in such position,  duties
or  responsibilities,  or a change in Executive's titles or offices,  as then in
effect,  or any removal of Executive  from, or any failure to reelect  Executive
to, any of such  positions,  except in connection  with the  termination  of his
employment  pursuant to subsections  5(a), 5(b) or 5(c); (iii) the relocation of
the  Company's  headquarters  to a place  more  than 30 miles  from its  present
location without the approval of the Executive; (iv) the occurrence of a Company
Illegal  Act; and (v) the  occurrence  of a Change of Control,  provided  that a
resignation  prior to the 90th day following such Change of Control shall not be
deemed a termination  for "Good  Reason." A "Company  Illegal Act" shall mean an
action  taken by the  Company  with the  approval  of the  Board  after  (1) the
Executive has notified the Board that he believes that the proposed  action will
result in a material  violation  of  federal or state law that will  result in a
material penalty for the Company and (2) the Board does not obtain an opinion of
its  outside  counsel in respect of the  proposed  action or it has  received an
opinion of its outside  counsel to the effect that such action is  substantially
likely to violate law and result in material penalty for the Company.  A "Change
of Control" shall occur when Vestar Equity Partners,  L.P. (1) no longer has the
legal right, directly or indirectly, to control the management of the Company or
its successor and (2) has  beneficial  ownership (as that term is defined in the
Securities Act of 1934),  whether held directly or indirectly,  of less than 50%
of the common equity  interests in the Company or its  successor  which have the
power to elect the Board,  provided that a Change of Control shall not result if
such change in beneficial  ownership occurs in connection with or after a public
offering of the common equity  interests in the Company or its  successor,  or a
corporation  formed pursuant to Section 10.5 of the Amended and Restated Limited
Liability  Company  Agreement of the Company  which  controls the Company or its
successor.  Notwithstanding the foregoing,  Executive shall be entitled to elect
to terminate  his  employment  for "Good  Reason"  only if  Executive  gives the
Company a Notice  of  Termination  notifying  the  Company  of his  election  to
terminate  employment  for "Good  Reason,"  within 90  business  days  after the
occurrence  of the event which  Executive  asserts as the basis for  Executive's
right to terminate his employment for "Good Reason."

                  (e) Termination by Company  Without Cause.  The Company may at
any time  terminate  the  Executive  for any reason and,  except for the amounts
payable  pursuant  to  subsection  6(a)  hereof,  Executive  shall have no claim
against  the  Company  under  this  Agreement  or  otherwise  by  reason of such
termination.  Termination of Executive's  employment pursuant to this subsection
5(e) shall be deemed to be exclusive of termination  under any other  subsection
of this Section 5 and of termination of Executive's  employment  upon expiration
of the Term of this Agreement.

                  (f) Notice of  Termination.  Any  termination  of  Executive's
employment by the Company or by Executive  (other than  termination  pursuant to
subsection  5(a) hereof) shall be  communicated by written Notice of Termination
to the other  party  hereto.  For  purposes  of this  Agreement,  a  "Notice  of
Termination"  shall mean a notice which shall indicate the specific  termination
provision in this Agreement relied upon and shall set forth in reasonable detail
the facts and circumstances,  if any, claimed to provide a basis for termination
of Executive's employment under the provision so indicated.

                  6.       COMPENSATION UPON TERMINATION

                  (a) If  Executive's  employment  is  terminated by the Company
pursuant to subsection  5(e),  or if Executive  shall  terminate his  employment
pursuant to subsection  5(d),  then  Executive  shall be entitled to receive the
Salary Severance  Benefit and the Bonus Severance Benefit in lieu of any further
salary and bonus or other  incentive  compensation  payments  to  Executive  for
periods  subsequent to the date of  termination.  Executive shall be entitled to
continue to  participate  in all Company  Benefit Plans on the same basis as the
Company's  executive  employees through the end of the fiscal year in which such
termination occurs,  provided that the Company shall continue to provide, at the
Company's  expense,  COBRA  benefits  required  to  be  provided  by  law  after
termination of  employment.  Notwithstanding  the  foregoing,  in the event that
Executive  terminates his employment  pursuant to Section 5(d) hereof on account
of a Change of Control, the period used to calculate payments under this Article
6 shall be eighteen  months,  provided,  however  that the amounts of salary and
bonus payable to Executive used to calculate the  termination  payments shall be
determined under this contract.

                  (b) If Executive's  employment terminates for any reason other
than pursuant to subparagraph 5(e) or 5(d), Executive shall receive compensation
and benefits through the end of the calendar month in which  termination  occurs
(or,  if  earlier,  the end of the Term then in  effect)  and  shall  thereafter
receive no other compensation or, except as required by law, any benefits of any
kind whatsoever; it being understood that no bonus shall be payable for the year
in which such termination occurs.

                  (c) Any sums due pursuant to the provisions of this subsection
6(a) shall be reduced by any sums payable to Executive  pursuant to any separate
severance or termination pay program maintained by the Company.

                  (d) For purposes of this Section 6, the following  terms shall
have the meaning set forth in this  subsection (d).  "Severance  Term" shall the
twenty-four  month period  commencing on the effective date of the  termination.
"Salary Severance Benefit" shall mean the sum of the salary that would have been
payable and the deferred compensation that would have accrued from the effective
date of  termination  through  the end of the  Severance  Term based on the Base
Salary in effect on the effective date of the termination.  The "Bonus Severance
Benefit"  shall  mean  the sum of (1) 100% of the  Annual  Severance  Bonus  (as
defined  below) for each fiscal year  ending in the  Severance  Term plus (2) an
amount equal to a pro rata portion of the Annual  Severance Bonus for the fiscal
year  beginning in but ending after the  Severance  Term (based on the number of
days of such fiscal year which are included in the  Severance  Term.  The Annual
Severance Bonus shall equal the bonus actually  payable in respect of the fiscal
year in which the termination occurs, provided, however, that if the termination
occurs in the first six months of the fiscal year,  the Annual  Severance  Bonus
shall equal the bonus  payable in respect of the  immediately  preceding  fiscal
year.

                  (e) The  Salary  Severance  Benefit  and the  Bonus  Severance
Benefit  shall be paid during the  Severance  Term in the same manner and on the
same dates that the salary  and bonus  would have been  payable  had he not been
terminated,  i.e., an amount equal to the Annual  Severance  Bonus shall be paid
when the bonus would be payable for each of the fiscal year in which termination
occurs and the next  succeeding  fiscal  year,  and the pro rata  portion of the
Annual  Severance  Bonus  will be paid when the bonus for the last  fiscal  year
beginning in the Severance Term is paid.

                  (f) In the event  that the  Company  elects  not to extend the
Term as provided in Section 2 hereof,  the  provisions of this  Agreement  shall
nevertheless continue to apply, except that the Severance Term shall be eighteen
months  from the date of  termination  of  employment,  and the Bonus  Severance
Benefit shall equal 150% of the Annual  Severance Bonus plus a pro rata share of
the  bonus for the  fiscal  year of the  Company  in which  the  termination  is
effective (based on the number of days elapsed through the date of termination).
and that the Executive may terminate his  employment at any time with or without
Good  Reason..  The  provisions  of Section 10 and 11 shall  continue  to apply,
except  that the  Noncompete  Period  shall  expire on the later to occur of the
first  anniversary of the date Executive's  employment is terminated or the last
day of the Severance Term, whichever is later.

                  (g) In the event that Executive is terminated without Cause by
         the  Company,  or Executive  resigns for Good  Reason,  within one year
         after a Change of  Control,  or if a Change of Control  follows  such a
         termination,  all  remaining  amounts  payable  under this Section 6 on
         account  of such  termination  shall be payable in a lump sum either on
         the effective date of such termination,  or upon the occurrence of such
         later Change of Control, as the case may be.

          7. ARBITRATION; LEGAL FEES; REIMBURSEMENT OF CERTAIN EXPENSES

                  (a) To the extent  that the  parties are unable to resolve any
disputes arising under this Agreement,  then either party may submit the dispute
to  binding  arbitration  in New York  City in  accordance  with the  rules  for
Employee  Dispute  Resolution of the American  Arbitration  Association  then in
effect  (and  the  Company  will  pay  all  filing  fees  for  commencing   such
arbitration).  The  arbitrator's  decision shall be made in accordance with such
rules,  shall be delivered in writing to the parties and shall be conclusive and
binding  upon the  parties.  Nothing in this  Section  7(a) shall  obligate  the
Company or entitle  Executive to submit any claim arising under Section 10 or 11
of this Agreement to arbitration or otherwise  limit the Company's  rights under
subsection 11(d).

                  (b) The Company  shall  promptly  reimburse  Executive for the
first  $50,000 of  reasonable  legal fees and  reasonable  expenses  incurred by
Executive  in  connection  with  seeking  to obtain or enforce in good faith any
right  or  benefit  provided  to  Executive  by the  Company  pursuant  to or in
accordance  with this  Agreement  and for 50% of all such  amounts  incurred  by
Executive in excess of $50,000 up to a maximum of $100,000 of aggregate benefits
paid under this  Section  7(b),  provided,  however,  that  notwithstanding  the
foregoing,  the Company  shall pay all of the  reasonable  expenses  incurred by
Executive if Executive prevails in such dispute. In addition, the Company hereby
agrees  that the  amount  of any such  legal  fees and  expenses  reimbursed  to
Executive  in  connection  with  obtaining  or  enforcing  any right or  benefit
provided to  Executive  by the Company  pursuant to or in  accordance  with this
Agreement  will not be taken into  account by the  Company  in  determining  the
aggregate  compensation paid or payable to Executive under this Agreement.  None
of the legal fees or reasonable  expenses paid to Executive by the Company under
this Section 7 shall be  recoverable.  The Company  shall bear its own costs and
attorneys' fees in any arbitration under this Agreement.

                  8.       INDEMNIFICATION

         The Company shall indemnify Executive (and his legal representatives or
other  successors),  unless expressly  prohibited by applicable law, against all
losses,  claims,  damages,  liabilities,  costs, charges and expenses whatsoever
(including  but not limited to all legal fees  payable to  attorneys  reasonably
acceptable to the Company and designated by Executive and any other expenses and
other  disbursements  incurred in connection  with  investigating,  preparing to
defend or defending  any action,  suit or  proceeding,  including any inquiry or
investigation,  commenced or threatened,  or in preparing to defend any claim or
threatened claim) incurred or sustained by him or his legal  representatives  in
connection  with any  action,  suit or  proceeding  to  which  he (or his  legal
representatives  or other successors) may be made a party by reason of his being
or having been a director,  officer or employee of the Company including payment
of expenses in advance of the final  disposition of the proceeding.  The Company
further agrees,  upon demand by Executive,  promptly to reimburse Executive for,
or pay,  any  loss,  claim,  damage,  liability  or  expense,  unless  expressly
prohibited  by  applicable  law, to which the  Company  has agreed to  indemnify
Executive pursuant to Sections 7 and 8 hereof. If any action, suit or proceeding
is brought or threatened  against Executive in respect of which indemnity may be
sought against the Company pursuant to the foregoing, Executive shall notify the
Company  promptly  in  writing  as  soon as  practicable  of the  threat  or the
institution of such action,  suit or proceeding.  Within 30 days of such notice,
the Company shall inform  Executive in writing  whether it elects to control and
direct the proceedings  relating to such action or claim.  If it so elects,  the
Company  shall  have the right to  direct,  control  and  supervise  Executive's
defense  of such  action,  suit or  proceeding  with  counsel  of the  Company's
choosing.  Executive may designate  separate  counsel,  at his own expense,  and
shall be entitled to  participate  in all aspects of the defense of such action,
suit or  proceeding.  If the Company  fails to elect to control the  proceeding,
Executive  shall direct and control the proceeding at Company's  expense and the
Company  shall have the right to  participate  in all  aspects of such  defense.
Neither  Executive nor the Company  shall settle or compromise  any such action,
suit or proceeding without the written consent of the other party hereto,  which
consent may not be unreasonably  withheld;  notwithstanding  the foregoing,  the
consent of  Executive  shall not be required if such  settlement  or  compromise
solely involves the payment of money or property by the Company or otherwise has
no adverse effect on Executive.  The Company shall continue to maintain officers
and  directors  liability  insurance  at the  levels  applicable  as of the date
hereof,  provided that the Company shall not be required to pay annual  premiums
that exceed 200% of the annual premiums in effect as of the date hereof.

                  9.       TAXES

                  The Company  shall deduct from all amounts  payable under this
Agreement  all  federal,  state,  local and other  taxes  required  by law to be
withheld with respect to such payments.

                  10.      CONFIDENTIALITY

                  Executive acknowledges that the information,  observations and
data obtained by him while  employed by the Company  concerning  the business or
affairs of the  Company  and its  subsidiaries  which are not  available  to the
public,  customers,  suppliers and  competitors  of the Company which are in the
nature of trade  secrets,  are  proprietary  or the  disclosure  of which  could
reasonably  be expected to cause a financial  loss to the Company,  or otherwise
have a material adverse effect on the Company  ("Confidential  Information") are
the property of the Company or such subsidiary. Therefore, Executive agrees that
he shall not disclose to any unauthorized  person or use for his own account any
Confidential  Information without the prior written consent of the Board, unless
and to the extent that the aforementioned  matters become generally known to and
available  for use by the public other than as a result of  Executive's  acts or
omissions to act.  Executive  shall deliver to the Company at the termination of
employment, or at any other time the Company may request, all memoranda,  notes,
plans,  records,  reports,  computer tapes and software and other  documents and
data (and copies thereof) relating to the Confidential Information, work product
or the  business  of the  Company or any of its  subsidiaries  which he may then
possess or have under his control.

                  11.      NON-COMPETE, NON-SOLICITATION

                  (a)  Executive  agrees that during the  Noncompete  Period (as
defined  below),  he shall not  directly or  indirectly  own,  manage,  control,
participate  in, consult with,  render  services for, or in any manner engage in
any business that  competes  anywhere in the United  States,  Canada or anywhere
else in the world with the  businesses  of the  Company or its  subsidiaries  as
businesses exist or are in process on the date of the termination of Executive's
employment. Nothing herein shall prohibit Executive from owning not more than 5%
of the outstanding  stock of any class of a corporation that is publicly traded,
so long  as  Executive  has no  active  participation  in the  business  of such
corporation.  For purposes of this Agreement, the term "Noncompete Period" means
the period  beginning on the date of this Agreement and ending on the earlier to
occur of (1) the first  anniversary of the last day of the Term and (2) the last
day of any Severance Term resulting from a termination of the Executive.

                  (b) Executive shall not directly or indirectly through another
entity (i) induce or attempt to induce any Senior  Executive  of the  Company or
its  subsidiaries to leave the employ of the Company or such  subsidiary,  or in
any way interfere with the relationship  between the Company or its subsidiaries
and any  Senior  Executive  thereof,  (ii)  hire  any  person  who was a  Senior
Executive  of the Company or its  subsidiaries  at any time  during  Executive's
employment  with the  Company  until the later of the first  anniversary  of the
termination of the Executive's  employment and the six month anniversary of such
Senior Executive's  departure from the Company, or (iii) for the two year period
after the  termination of his  employment  with the Company induce or attempt to
induce any  customer,  supplier,  licensee  or other  business  relation  of the
Company or its  subsidiaries  to cease  doing  business  with the Company or its
subsidiaries,  or in any way interfere  with the  relationship  between any such
customer,  supplier,  licensee  or  business  relation  and the  Company  or its
subsidiaries.  "Senior  Executive"  shall mean any  employee of the Company with
significant managerial responsibility over material areas of the business of the
Company,   including,   without   limitation,   financial,   marketing,   sales,
distribution or manufacturing.

                  (c) If, at the time of enforcement of this Section 11, a court
or arbitrator shall hold that the duration,  scope or area  restrictions  stated
herein are unreasonable  under  circumstances  then existing,  the parties agree
that the maximum  duration,  scope or area reasonable  under such  circumstances
shall be substituted for the stated  duration,  scope or area and that the court
or arbitrator  shall be allowed to revise the  restrictions  contained herein to
cover the maximum period, scope and area permitted by law.

                  (d) In the  event of the  breach  or a  threatened  breach  by
Executive,  of any of the  provisions  of  Section  10 or this  Section  11, the
Company,  in addition and supplementary to other rights and remedies existing in
its favor, may apply to any court of law or equity of competent jurisdiction for
specific  performance  or  injunctive  or other  relief in order to  enforce  or
prevent any violations of the provisions hereof (without posting a bond or other
security).

                  12.      SUCCESSORS; BINDING AGREEMENT

                  (a) This  Agreement  shall be  binding  upon and  inure to the
benefit  of the  Company  and  any  successor  of the  Company,  including,  any
corporation  acquiring  directly or indirectly all or  substantially  all of the
membership  Units,  business  or  assets  of the  Company,  whether  by  merger,
restructuring,  reorganization,  consolidation,  sale  or  otherwise  (and  such
successor  shall  thereafter  be deemed the  "Company"  for the purposes of this
Agreement).  Each of the Company's  subsidiaries  are hereby  acknowledged to be
third-party  beneficiaries  with respect to the provisions of Sections 10 and 11
hereof and shall be entitled to enforce such  provisions as if they were parties
hereto.

                  (b) This Agreement and all rights of Executive hereunder shall
inure to the  benefit of and be  enforceable  by  Executive's  personal or legal
representatives,  executors,  administrators,  successors,  heirs, distributees,
devisees and legatees.  If Executive should die while any amounts would be still
payable to him hereunder if he had continued to live,  all such amounts,  unless
otherwise  provided  herein,  shall be paid in accordance with the terms of this
Agreement to Executive's devisee,  legatee, or other beneficiary or, if there be
no such beneficiary, to Executive's estate.

                  13.      NOTICE

                  For the purposes of this Agreement,  notices,  demands and all
other communications provided for in the Agreement shall be in writing and shall
be deemed to have been duly  given  when hand  delivered  or  (unless  otherwise
specified)  when  mailed  by  United  States  certified  mail,   return  receipt
requested, postage prepaid, addressed as follows:

                  If to Executive:

                  Neil P. DeFeo
                  21 Woody Lane
                  Westport, Connecticut  06880

                  If to the Board or the Company:
                  ------------------------------

                  Remington Products Company, L.L.C.
                  c/o Vestar Capital Partners
                  245 Park Avenue, 41st Floor
                  New York, New York  10167
                  Attention:  Robert L. Rosner
                                 Jack M. Feder

                  If to the Company:

                  Remington Products Company
                  60 Main Street
                  Bridgeport, Connecticut  06604
                  Attention:  General Counsel

or to such  other  address  as any party  may have  furnished  to the  others in
writing in accordance  herewith,  except that notices of change of address shall
be effective only upon receipt.

                  14.      SURVIVORSHIP

                  The   respective   rights  and   obligations  of  the  parties
hereunder,  including the rights and  obligations set forth in Sections 6, 7, 8,
9, 10 and 11 of this Agreement,  shall survive any termination of this Agreement
to the  extent  necessary  to the  intended  preservation  of  such  rights  and
obligations.  In addition,  the terms of this Agreement shall continue in effect
as provided in Section 6(g).

                  15.      REPRESENTATIONS AND WARRANTIES

                  The  Company  represents  and  warrants  that  (a) it is fully
authorized  and  empowered to enter into this  Agreement  and that the Board has
approved the terms of this  Agreement,  (b) the execution of this  Agreement and
the  performance  of its  obligations  under this  Agreement will not violate or
result in a breach of the terms of any  material  agreement to which the Company
is a party or by which it is bound, no approval by any governmental authority or
body is required for it to enter into this  Agreement,  and (d) the Agreement is
valid, binding and enforceable against the Company in accordance with its terms,
except to the extent affected or limited by applicable  bankruptcy laws or other
statutes  governing  the right of creditors  generally  and any  regulations  or
interpretations thereof. Executive represents and warrants that his execution of
this Agreement and his performance of his duties and responsibilities under this
Agreement  will not  violate or result in a breach of the terms of any  material
agreement to which he is a party or by which he is bound.

                  16.      MISCELLANEOUS

                  The parties  hereto  agree that this  Agreement  contains  the
entire  understanding  and agreement  between  them,  and  supersedes  all prior
understandings  and agreements  between the parties respecting the employment by
the Company of Executive,  and that the  provisions of this Agreement may not be
modified, waived or discharged unless such waiver,  modification or discharge is
agreed to in writing  signed by the parties  hereto.  No waiver by either  party
hereto at any time of any breach by the other  party  hereto  of, or  compliance
with, any condition or provision of this Agreement to be performed by such other
party shall be deemed a waiver of similar or dissimilar provisions or conditions
at  the  same  or  at  any  prior  or   subsequent   time.   No   agreements  or
representations,  oral or  otherwise,  express or implied,  with  respect to the
subject  matter  hereof  have been made by either  party which are not set forth
expressly in this Agreement.  The validity,  interpretations,  construction  and
performance of this Agreement  shall be governed by the laws of the State of New
York without giving effect to the conflict of laws principles thereof.

                  17.      VALIDITY

                  The  invalidity  or   unenforceability  of  any  provision  or
provisions of this Agreement shall not affect the validity or  enforceability of
any other provision or provisions of this Agreement,  which shall remain in full
force and effect.

                  18.      COUNTERPARTS

                  This  Agreement  may be executed in one or more  counterparts,
each of which shall be deemed to be an original but all of which  together  will
constitute one and the same instrument.

<PAGE>

         IN WITNESS WHEREOF,  the parties hereto have executed this Agreement as
of the date and the year first above written.

                                       REMINGTON PRODUCTS COMPANY, L.L.C.

                                       By:        /s/ Neil P. DeFeo
                                          --------------------------------------
                                          Name:   NEIL P. DEFEO
                                          Title:  Chief Executive Officer and
                                                  President

                                          --------------------------------------EXHBIIT 10.12

                          TERMINATION AGREEMENT

     This TERMINATION AGREEMENT (this "Agreement") is made as of July 10,
2000 by and among WESTERN CENTER FOR CLINICAL STUDIES, a California
corporation ("WCCS"), and ENTROPIN, INC., A Colorado corporation
("Entropin") (WCCS and Entropin may be referred to herein as the "parties").

                                RECITALS

     WHEREAS, WCCS and Entropin entered into that certain Agreement dated
April 6, 1998, as amended by that certain Second Amendment dated July 21,
1999, that certain Third Amendment dated November 10, 1999, that certain
Amendment dated March 6, 2000, and that certain Amendment dated May 17,
2000 (collectively the agreement as amended shall be referred to herein as,
the "WCCS Agreement") whereby WCCS agreed to perform certain services for
Entropin related to the clinical trials for a new drug product known as
Esterom;

     WHEREAS, WCCS and Entropin entered into that certain WCCS Wrap Around
Agreement dated November 10, 1999 (the "Wrap Around Agreement") where WCCS
agreed to assume certain responsibilities under its agreement with
Therapeutic Management Agreement (the WCCS Agreement and the Wrap Around
Agreement shall collectively be referred to herein as, the "Trial
Agreements"); and

     WHEREAS, WCCS and Entropin desire to terminate the Trial Agreements
and reach a mutually beneficial settlement of the remaining issues;

     NOW, THEREFORE, for mutual consideration contained herein, the
sufficiency of which is hereby acknowledged, WCCS and Entropin hereby agree
as follows:

                                AGREEMENT

     SECTION 1.  TERMINATION.   Pursuant to Section 7.6 of the WCCS
Agreement, the parties hereby agree to terminate the Trial Agreements and
any other related agreements, whether written or oral, as of the date
hereof and upon the terms and conditions set forth herein.

     SECTION 2.  RETURN OF PROPERTY.  The parties hereby agree to return
the property of the other as set forth below:

          2.1  EQUIPMENT AND FURNITURE.   All furniture and equipment
     shall be retained by WCCS as its sole and exclusive property.

          2.2  CONFIDENTIAL INFORMATION OF ENTROPIN.   Not later than July
     20, 2000, WCCS working in a cooperative and concerted effort with
     Entropin's designated representative or representatives (i) shall
     return all Entropin's Confidential Information (as defined in the WCCS
     Agreement), including, without limitation, all documentation related
     to the clinical trials and electronic form of any such

<PAGE>
     information to Entropin, and (ii) shall provide an index of all
     documentation related to the clinical trials which has been returned
     to Entropin.  Entropin's designated representative shall promptly
     review such information and index upon its receipt, in whole or in
     part, and if Entropin's designated representative reasonably believes
     that any of Entropin's Confidential Information is missing, such
     representative shall promptly inform WCCS, and WCCS shall promptly
     provide such Confidential Information or a written, executed
     explanation on WCCS Letterhead stating where such Information can be
     obtained or why such Information is not in the possession of WCCS.

          2.3  CONFIDENTIAL INFORMATION OF WCCS   All WCCS Confidential
     Information (as defined in the WCCS Agreement), if any, shall be
     returned within five (5) days from the date of this Agreement to, or
     retained by, WCCS.  In the event that WCCS reasonably believes that
     any WCCS Confidential Information has not been returned, a duly
     authorized officer or representative of WCCS shall deliver notice to
     Entropin setting forth a description of the document or information to
     be returned.  Within five (5) days of receiving such notice, Entropin
     shall deliver the WCCS Confidential Information to an authorized
     officer or representative of WCCS, or a written, executed explanation
     on Entropin Letterhead of why such information is no longer in the
     possession of Entropin.

WCCS hereby acknowledges that this Agreement and all payments and
considerations to be received hereunder from Entropin are conditioned on
the return of all material Confidential Information to Entropin and the
further agreement of WCCS to cooperate with Entropin, the Food and Drug
Administration ("FDA") and the Drug Enforcement Agency ("DEA") with respect
to WCCS' work during the term of the Trial Agreements.  Entropin agrees to
reimburse WCCS for its reasonable out of pocket expenses incurred in
connection with such cooperation.  Notwithstanding the condition set forth
at the beginning of this paragraph, Entropin agrees that so long as WCCS
provides the written explanation contemplated in Section 2.2, the absence
of any Confidential Information will not be a basis for non-payment of the
consideration to be received by WCCS under this Agreement, nor shall it
constitute a claim by Entropin under the Carve Out as defined in Section
6.1 of this Agreement.

     SECTION 3.  PAYMENT FOR SERVICES RENDERED.   Upon the completion of
the delivery of Entropin's Confidential Information required hereunder in
accordance with the preceding Section, Entropin agrees to deliver to WCCS
or its authorized representative $71,600 by certified check.  WCCS hereby
agrees to accept $71,600 as payment in full for all amounts due, as of the
date hereof, under the Trial Agreements for the services of WCCS, in
addition to the consideration set forth in the following Section.

     SECTION 4.  OPTIONS TO PURCHASE THE COMMON STOCK OF ENTROPIN.   As
additional consideration for this Agreement and upon completion of the
delivery of Entropin's Confidential Information required hereunder in
accordance with Section 2, Entropin hereby agrees to deliver an option to
purchase 75,000 shares of the common stock of Entropin with an exercise
price of $1.50 per share and an option to purchase 90,000 shares of the
common stock of Entropin with an exercise price of $2.50 per share, all or
a portion of such exercise may be done by cashless

                                   -2-
<PAGE>
exercise.  Such options shall be fully vested, but subject to all
restrictions and lock-up agreements required by the Securities and Exchange
Commission and all State securities commissions which, Entropin represents,
restricts the sale of securities underlying such options until March 20,
2001.  The shares underlying such options are registered under all
applicable securities laws and upon the exercise of such options, the
shares shall be subject only to the restrictions set forth in the Lock-Up
Agreements previously executed by WCCS and its principals.

     SECTION 5.  SCIENCE MEDICAL ADVISORY BOARD.   WCCS has entered into
agreements with certain individuals as members of a Science Medical
Advisory Board ("SMAB").  Under such agreements, WCCS has promised options
to purchase the common stock of Entropin.  The SMAB agreements are in
writing and executed by each member of the SMAB.  WCCS hereby agrees to
take all reasonable action to obtain the agreement of each SMAB member to
the assignment of his/her agreement to Entropin on or prior to July 20,
2000.  Dan Azarnoff shall work together with Thomas Tachovsky to contact
each SMAB member and obtain their consent to such assignment.  Upon such
assignment, Entropin agrees to the terms and conditions of such agreements,
including the delivery of options to such members.

     SECTION 6.  GENERAL RELEASE AND INDEMNIFICATION.

     6.1. Entropin, on behalf of itself and its officers, directors,
     shareholders, agents, employees, attorneys, representatives,
     affiliates, subsidiaries, administrators, successors and assigns
     (collectively the "Entropin Releasors"), for good and sufficient
     consideration, receipt of which is hereby acknowledged, releases
     and forever discharges each and every liability, claim, right and
     cause of action, whether in law or equity, whether known or
     unknown, that the Entropin Releasors or any of them had, now have
     or may hereafter have against WCCS, its officers, directors,
     shareholders, agents, employees, attorneys, representatives,
     affiliates, subsidiaries, administrators, successors and assigns
     (collectively the "WCCS Releasees") or any of them arising out of
     or in any way related to, the performance or non-performance, or
     in any other way related to the Trial Agreements (the "Entropin
     Released Claims") and agrees to indemnify, defend and hold
     harmless the WCCS Releasees from and against any and all damages,
     claims, losses, expenses, costs, obligations and liabilities,
     including without limitation, liabilities for reasonable
     attorneys' fees, arising out of or in any way related to the
     Entropin Released Claims; provided, however, that this Release
     does not release any party from its obligations under this
     Agreement and provided further that this release and
     indemnification shall not apply to any liability incurred by WCCS
     due to WCCS's gross negligence, intentional misconduct, or
     violations of material laws, regulations and policies of the
     United States, the FDA and the DEA (such laws, regulations and
     policies shall be referred to herein as, the "Legal
     Requirements") (such proviso for gross negligence, intentional
     misconduct and violation of certain laws shall be referred to
     herein as a "Carve Out"); provided, further, that Entropin shall
     indemnify and hold WCCS harmless for any liability incurred by
     WCCS for Entropin's gross negligence, intentional misconduct or
     violation of the Legal Requirements.

                                   -3-
<PAGE>
     6.2. WCCS, on behalf of itself and its officers, directors,
     shareholders, agents, employees, attorneys, representatives,
     affiliates, subsidiaries, administrators, successors and assigns
     (collectively the "WCCS Releasors"), for good and sufficient
     consideration, receipt of which is hereby acknowledged, releases
     and forever discharges each and every liability, claim, right and
     cause of action, whether in law or equity, whether known or
     unknown, that the WCCS Releasors or any of them had, now have or
     may hereafter have against Entropin, its officers, directors,
     shareholders, agents, employees, attorneys, representatives,
     affiliates, subsidiaries, administrators, successors and assigns
     (collectively the Entropin Releasees") or any of them arising out
     of or in any way related to, the performance or non-performance,
     or in any other way related to the Trial Agreements (the "WCCS
     Released Claims") and agrees to indemnify, defend and hold
     harmless the Entropin Releasees from and against any and all
     damages, claims, losses, expenses, costs, obligations and
     liabilities, including without limitation, liabilities for
     reasonable attorneys' fees, arising out of or in any way related
     to the WCCS Released Claims; provided, however, that this Release
     does not release any party from its obligations under this
     Agreement and provided further that this release and
     indemnification shall not apply to any liability incurred by
     Entropin due to Entropin's gross negligence, intentional
     misconduct, or violations of the Legal Requirements; provided,
     further, that WCCS shall indemnify and hold Entropin harmless for
     any liability incurred by Entropin for WCCS's gross negligence,
     intentional misconduct or violation of the Legal Requirements.

     SECTION 7.  DISPARAGING REMARKS.   The parties hereby agree not to
make any disparaging remarks about the other party or participate in any
press releases which discuss any specific reasons for termination of the
Agreement, other than completion of the services rendered as of the date
hereof.  Entropin further agrees that certain Memorandum to its counsel
dated July 7, 2000 shall be maintained as confidential information and it
shall not be disclosed to any third party, except in the event of, and only
in connection with, subsequent litigation between WCCS and Entropin or as
otherwise may be required by law or regulations.

     SECTION 8.  NOTICES.   All notices, requests, demands and other
communications pertaining to this Agreement shall be in writing and shall
be given by hand delivery, by prepaid registered or certified mail with
return receipt requested, by an established national overnight courier
providing proof of delivery for next business day delivery, or by
facsimile, addressed as follows:

          If to WCCS:

               Western Center for Clinical Studies, Inc.
               Suite 810
               21550 Oxnard Street
               Woodland Hills, CA 91367
               Attention:  Dr. Roy Azarnoff
               Facsimile No.:  (818) 676-0010

                                   -4-
<PAGE>
          with a copy (which shall not constitute notice) to:

               Musick, Peeler & Garrett LLP
               Suite 2000
               One Wilshire Boulevard
               Los Angeles, CA 90017-3321
               Attention:  Joseph J. McCann, Jr., Esq.
               Facsimile No.:  (213) 624-1376

          If to Entropin:

               Entropin, Inc.
               45926 Oasis Street
               Indio, CA 92201
               Attention:  Dr. Thomas G. Tachovsky
               Facsimile No.:  (760) 347-6563

          with a copy (which shall not constitute notice) to:

               Brenman Bromberg & Tenenbaum, P.C.
               Suite 1001
               Mellon Financial Center
               1775 Sherman Street
               Denver, CO 80203-4314
               Attention:  A. Thomas Tenenbaum, Esq.
               Facsimile No.:  (303) 839-1633

The date of any such notice and service thereof shall be deemed to be (i)
the date of delivery if hand-delivered or delivered by overnight courier,
(ii) the date of delivery as indicated on the return receipt if dispatched
by mail, or (iii) the date of facsimile transmission as indicated on the
facsimile transmission report, provided that any facsimile transmission
shall not be effective unless a paper copy is sent by overnight courier on
the date of the facsimile transmission.  Any party may change its address
for notice by notice to the others given pursuant to the requirements of
this Section.

     SECTION 9.  FURTHER ASSURANCES.   Each party shall execute and deliver
such additional documents and take further actions as are reasonably
necessary for the purposes of carrying out this Agreement.

     SECTION 10.  BINDING EFFECT.   This Agreement shall be binding upon
and shall inure to the benefit of the parties hereto and their respective
successors and assigns.

     SECTION 11.  ENTIRE AGREEMENT.   This Agreement, the Schedules and
Exhibits hereto constitute the entire agreement and understanding of the
parties hereto and supersede any and all prior agreements, arrangements and
understandings related to the matters provided for herein.

                                   -5-
<PAGE>
     SECTION 12.  AMENDMENT.   This Agreement may be modified or amended
only in a writing signed by the parties hereto.

     SECTION 13.  WAIVER.   No waiver by any party hereto of a breach by
another party hereto of any provision of this Agreement shall be deemed to
constitute a waiver of any proceeding or subsequent breach of the same
provisions or any other provision.

     SECTION 14.  HEADINGS.   The headings set forth in this Agreement are
for convenience only and shall not control or affect the meaning or
construction of the provisions of this Agreement.

     SECTION 15.  GOVERNING LAW.   The construction and performance of this
Agreement shall be governed by the laws of the State of Colorado without
regard to its conflict of laws principles.

     SECTION 16.  COUNTERPARTS.   This Agreement may be executed in one or
more counterparts, each of which will be deemed an original and all of
which together will constitute one and the same instrument.  A facsimile
signature shall have the same effect as an original signature provided that
the original signature page is sent by overnight courier on the same date
as the facsimile is delivered.

     SECTION 17.  NO ADMISSION.   Neither party, by execution of this
Agreement, or otherwise is making an admission of wrongdoing, negligence or
any other culpability.  This Agreement is only a document for the
termination of the Trial Agreements.

     SECTION 18.  ARBITRATION, DISPUTE RESOLUTION.   Any controversy or
claim arising out of or relating to this Agreement, or breach thereof,
shall be settled by arbitration.  The arbitration shall be administered by
the Denver, Colorado office of the American Arbitration Association in
accordance with the then current Commercial Arbitration Rules of the
American Arbitration Association.  Such arbitration proceedings shall be
conducted in Denver, Colorado, or such other location as the parties may
agree.  The dispute will be heard by a panel of three arbitrators, each
with a familiarity with pharmaceutical manufacturing and/or pharmaceutical
research and development.  One arbitrator shall be appointed by each of the
parties and the third appointed by the other two arbitrators.  The
determination of the arbitrators shall be conclusive and binding upon both
parties.  The parties acknowledge and agree that any arbitration judgment
may be enforced against either or both of them in a court of competent
jurisdiction.  The arbitrators' award as to the payment of the costs of
arbitration shall be binding upon the parties.  The prevailing party in any
arbitration conducted in accordance with this paragraph will be entitled to
attorneys' fees and costs.

     SECTION 19.  CONFIDENTIALITY.   The parties hereby acknowledge that
their respective obligations under that Confidentiality Agreement dated
April 6, 1998, survive this Termination.

                    [See Page 7 for Signature Pages]

                                   -6-
<PAGE>
     IN WITNESS WHEREOF, the parties have set forth their respective
signatures on this Agreement as of the date first set forth above.

                              ENTROPIN, INC., a Colorado corporation

                              By:  \s\ Thomas G. Tachovsky
                                 ---------------------------------------
                              Name:  Thomas G. Tachovsky
                              Title: President and Chief Executive Officer

                              WESTERN CENTER FOR CLINICAL
                              STUDIES, INC., a California corporation

                              By:  \s\ Daniel L. Azarnoff
                                 ---------------------------------------
                              Name:  Dan Azarnoff
                              Title: Vice President

                                   -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]